The estimated Net Worth of Kim Kelderman is at least $6.68 million dollars as of 29 August 2024. Mr. Kelderman owns over 1,492 units of Bio-Techne Corp stock worth over $3,044,985 and over the last 7 years he sold TECH stock worth over $1,464,008. In addition, he makes $2,175,310 as President - Diagnostics and Genomics at Bio-Techne Corp.
Sign up
Mr. Kelderman TECH stock SEC Form 4 insiders trading
Kim has made over 16 trades of the Bio-Techne Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 1,492 units of TECH stock worth $99,919 on 29 August 2024.
The largest trade he's ever made was exercising 14,000 units of Bio-Techne Corp stock on 31 July 2024 worth over $527,800. On average, Kim trades about 1,646 units every 78 days since 2018. As of 29 August 2024 he still owns at least 41,434 units of Bio-Techne Corp stock.
You can see the complete history of Mr. Kelderman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kim Kelderman biography
Kim Kelderman is President - Diagnostics and Genomics of the Company. Prior to Bio-Techne, Mr. Kelderman was employed at Thermo Fisher Scientific where he led three different businesses of increasing scale and complexity. For the last three years, Mr. Kelderman managed the Platforms and Content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kim served as Senior Segment Leader at Becton Dickinson, managing the global Blood Tubes “Vacutainer” business.
What is the salary of Kim Kelderman?
As the President - Diagnostics and Genomics of Bio-Techne Corp, the total compensation of Kim Kelderman at Bio-Techne Corp is $2,175,310. There are 4 executives at Bio-Techne Corp getting paid more, with Charles Kummeth having the highest compensation of $11,483,800.
How old is Kim Kelderman?
Kim Kelderman is 53, he's been the President - Diagnostics and Genomics of Bio-Techne Corp since 2018. There are 15 older and 3 younger executives at Bio-Techne Corp. The oldest executive at Bio-Techne Corp is Roeland Nusse, 70, who is the Independent Director.
What's Kim Kelderman's mailing address?
Kim's mailing address filed with the SEC is 614, Northeast McKinley Place, Minneapolis, Hennepin County, Minnesota, 55413, United States.
Insiders trading at Bio-Techne Corp
Over the last 21 years, insiders at Bio-Techne Corp have traded over $37,160,097 worth of Bio-Techne Corp stock and bought 4,361 units worth $454,370 . The most active insiders traders include Charles R. Kummeth, Rupert Vessey et John L Higgins. On average, Bio-Techne Corp executives and independent directors trade stock every 23 days with the average trade being worth of $964,850. The most recent stock trade was executed by Kim Kelderman on 29 August 2024, trading 1,492 units of TECH stock currently worth $99,919.
What does Bio-Techne Corp do?
bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.
What does Bio-Techne Corp's logo look like?
Complete history of Mr. Kelderman stock trades at Bio-Techne Corp
Bio-Techne Corp executives and stock owners
Bio-Techne Corp executives and other stock owners filed with the SEC include:
-
Charles Kummeth,
President, Chief Executive Officer, Director -
Charles R. Kummeth,
CEO, Pres & Director -
James Hippel,
Chief Financial Officer, Executive Vice President - Finance -
David Eansor,
President - Protein Sciences -
Kim Kelderman,
President - Diagnostics and Genomics -
Brenda Furlow,
Senior Vice President, General Counsel, Corporate Secretary -
James T. Hippel,
Exec. VP of Fin. & CFO -
Norman David Eansor,
Pres of Protein Sciences Segment -
Kim Kelderman,
Pres of Diagnostics & Genomics -
Brenda S. Furlow J.D.,
Exec. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Robert Baumgartner,
Independent Chairman of the Board -
Rupert Vessey,
Independent Director -
John Higgins,
Independent Director -
Randolph Steer,
Independent Director -
Roeland Nusse,
Independent Director -
Alpna Seth,
Independent Director -
Joseph Keegan,
Independent Director -
David Clair,
IR Contact Officer -
Julie Bushman,
Independent Director -
Kevin Smyth,
Sr. VP & Chief Digital Officer -
Luca Cicchetti,
Managing Director -
Brenda Everson,
Sr. VP of HR -
Kevin S. Gould,
Sr. VP of Diagnostics Reagents Division -
Struan Robertson,
VP of HR -
Robert M. Gavin,
VP of Corp. Devel. -
Gerry Andros,
VP of Sales and Marketing -
Karen A Holbrook,
Director -
Roger C Lucas,
-
Charles A Dinarello,
-
J. Fernando Bazan,
Chief Technical Officer -
Robert M. Gavin,
Sen. VP Protein Platforms -
Kevin S Gould,
SVP Clinical Controls -
Kevin J Reagan,
Senior VP Biotech -
Gregory J Melsen,
VP Finance and CFO -
Thomas E Oland,
President -
Howard V Oconnell,
Director -
Marcel Veronneau,
Vice Pres-Hematology Oper. -
James A Weatherbee,
Chief Scientific Officers -
Monica Tsang,
Vice President of Research -
Christopher S Henney,
Director -
G A Herbert,
Director -
Harold J Wiens,
-
William Geist,
PRESIDENT, PROTEIN SCIENCES -
Shane Bohnen,
SVP - General Counsel -
Matthew Mc Manus,
President - DGS -
Judith V Klimovsky,
Director